Innocan Pharma boasts impressive achievements in efficacy tests, commercialization and IP

Ronald Kaufman Independent Analyst

Innocan Pharma Corporation (CSE: INNO, FSE: IP4), a pharmaceutical tech company, has announced significant achievements over the past few weeks in drug delivery platform technologies, efficacy tests, commercialization and intellectual property (IP) development in the cannabis industry.

The company has filed a joint patent application with Ramot at Tel Aviv University with the World Intellectual Property Organization to develop a drug delivery platform that maximizes the activity of loaded cannabinoids. Innocan's innovative platform aims to load cannabinoids on exosomes to expand the IP space for cannabis-based products. Innocan's CEO, Iris Bincovich, noted that the joint application reflects the strength of their collaboration and the potential of their partnership.

Innocan Pharma's portfolio of targeted healing products continues to expand, positioning the company as a leader in the field of cannabis-based therapeutics. The company has reported successful results of an efficacy test for its vaginal derma product that contains cannabinoids, phytoestrogens, hyaluronic acid, and probiotics. The product offers a healthy alternative for women seeking relief from vaginal discomfort and has been proven effective in a 56-day trial conducted with a group of female volunteers.

The pharmaceutical tech company has also launched a CBD veterinary commercialization team dedicated to licensing and commercializing their CBD therapy in the veterinary field. The company plans to engage with prospective clients to explore potential collaborations and commercialization opportunities. The company believes that the veterinary market represents a significant opportunity for growth and expansion.

Moreover, Innocan Pharma has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application related to a combined cannabis and magnesium topical pain-relief technology. The patent covers breakthrough technology designed to relieve pain and itching topically using spray, roll-on, or lotion. The patent approval would aid the company's commercialization efforts.

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies, comprising cannabinoids science, to treat various conditions to improve patients' quality of life. The Consumer Wellness segment develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle.

While Innocan has outpaced the CSE and HMMJ (Horizons Marijuana Life Sciences Index) over the past three months, it still seems that there is potentially substantial room for gains given its impressive milestones.

Innocan Pharma's recent achievements in drug delivery platform technologies, efficacy tests, commercialization, and IP development in the CBD and Pharma industry are impressive. The company's dedication to improving patients' quality of life through innovative technologies and consumer wellness products positions Innocan as a leader in the CBD-based therapeutics and care markets. As the company continues to expand its portfolio of targeted healing products and patent application filings, it's exciting to see what other breakthroughs Innocan Pharma will bring to the cannabis industry in the near future.

Author

Ronald Kaufman

Independent Analyst

Ronald Kaufman a writer and blogger active in the fields of foodtech, pharma, cyber, biotech and more. Ronald writes for leading publications about a number of topics.

GBP/USD hits multi-week tops around 1.3560

GBP/USD gathers fresh steam and advances to new three-month peaks near the 1.3560 zone on Friday. Cable’s sharp move higher comes after three daily drops in a row and follows the increasing selling pressure hurting the Greenback.

EUR/USD pops to fresh two-month highs, targets 1.1600

EUR/USD advances markedly, revisiting the upper 1.1500s for the first time since mid-June. The pair’s sharp uptick comes on the back of a strong retracement in the US Dollar amid BoJ intervention chatter and despite steady uncertainty in the Middle East.

Gold picks up pace, approaches $4,400

Gold rebounds toward the $4,400 mark per troy ounce on Friday, reversing the previous day’s pullback. The precious metal’s recovery comes as fresh and intense weakness keep weighing on the US Dollar, while traders keep assessing easing expectations of an imminent Fed interest rate hike and the situation from the Middle East.

Pi Network Price Forecast: PI extends consolidation as bulls eye $0.10

Pi Network (PI) price holds steady on Friday, maintaining a consolidating tone for three consecutive days. Mild retail strength in the PI token remains stable, with Open Interest above $9 million, while social buzz eases. PI token’s technical outlook is mixed, as bearish momentum wanes to neutral, with bulls eyeing the $0.1000 psychological level.

Weekly focus: Some relief in US inflation concerns

Actual inflation data for July came out as expected with a 0.1% m/m increase in headline CPI and 0.2% excluding food and energy. Annual headline inflation remains too high at 3.4% and means that wage earners are experiencing stagnating spending power at best, and core inflation is a bit higher than the inflation target of two percent would suggest.

Why is Crude Oil priced for a reopening the ships haven't made?

Fourteen vessels crossed the Strait of Hormuz on Tuesday. Before the war, the count ran near 120 a day. In the sessions since the waterway was publicly declared open, Brent has drifted back to $87 and West Texas Intermediate (WTI) to $81, both a little lower again on Wednesday, with daily momentum on each unwound from the top of its range in late July to the low twenties now.